PAVmed (NASDAQ:PAVM) Chairman Lishan Aklog acquired 2,200 shares of the business’s stock in a transaction dated Wednesday, November 23rd. The shares were bought at an average price of $8.98 per share, with a total value of $19,756.00. Following the transaction, the chairman now directly owns 25,600 shares in the company, valued at approximately $229,888. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Lishan Aklog also recently made the following trade(s):

  • On Monday, November 21st, Lishan Aklog acquired 2,300 shares of PAVmed stock. The shares were bought at an average price of $10.02 per share, with a total value of $23,046.00.
  • On Friday, September 16th, Lishan Aklog acquired 1,300 shares of PAVmed stock. The shares were bought at an average price of $14.05 per share, with a total value of $18,265.00.
  • On Wednesday, September 14th, Lishan Aklog acquired 1,500 shares of PAVmed stock. The shares were bought at an average price of $13.40 per share, with a total value of $20,100.00.

Shares of PAVmed (NASDAQ:PAVM) opened at 8.7073 on Wednesday. The firm’s market cap is $115.89 million. The stock’s 50 day moving average price is $11.06 and its 200-day moving average price is $12.79. PAVmed has a 12 month low of $8.71 and a 12 month high of $15.24.

TRADEMARK VIOLATION WARNING: “Lishan Aklog Purchases 2,200 Shares of PAVmed (PAVM) Stock” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of US and international trademark & copyright laws. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2016/11/30/lishan-aklog-purchases-2200-shares-of-pavmed-pavm-stock.html.

5 Day Chart for NASDAQ:PAVM

Receive News & Stock Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related stocks with our FREE daily email newsletter.